Literature DB >> 6508979

Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

M W Teunissen, W Bakker, J E Meerburg-Van der Torren, D D Breimer.   

Abstract

The influence of an 8-day therapy with rifampicin (600 mg daily) was studied on antipyrine plasma clearance and metabolite formation in seven patients with tuberculosis (age 18-79 years), who were also treated with isoniazid and pyrazinamide. After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05). Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed. The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min. Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine. Other pathways of antipyrine metabolism were hardly affected. This provides further evidence for the involvement of different iso-enzymes of the cytochrome P-450 system in antipyrine metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508979      PMCID: PMC1463547          DOI: 10.1111/j.1365-2125.1984.tb02532.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

Review 3.  Genetic and environmental factors affecting drug disposition in man.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

4.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

5.  [The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives].

Authors:  D Reimers; A Jezek
Journal:  Prax Pneumol       Date:  1971-05

6.  Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.

Authors:  M W Teunissen; J E Meerburg-van der Torren; N P Vermeulen; D D Breimer
Journal:  J Chromatogr       Date:  1983-12-09

7.  Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man.

Authors:  A Kappas; K E Anderson; A H Conney; A P Alvares
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

8.  Pharmacokinetic interactions with rifampicin.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

10.  Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.

Authors:  D D Breimer; W Zilly; E Richter
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

View more
  9 in total

1.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  The effect of rifampicin on the pharmacokinetics of doxycycline.

Authors:  A Garraffo; P Dellamonica; J P Fournier; P Lapalus; E Bernard
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

3.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

4.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

6.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

7.  Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers.

Authors:  Margherita Strolin Benedetti; Rhys Whomsley; Jean-Marie Nicolas; Colin Young; Eugène Baltes
Journal:  Eur J Clin Pharmacol       Date:  2003-10-07       Impact factor: 2.953

8.  Rifampin Pharmacokinetics and Safety in Preterm and Term Infants.

Authors:  P Brian Smith; C Michael Cotten; Mark L Hudak; Janice E Sullivan; Brenda B Poindexter; Michael Cohen-Wolkowiez; Felix Boakye-Agyeman; Andrew Lewandowski; Ravinder Anand; Daniel K Benjamin; Matthew M Laughon
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.938

Review 9.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Authors:  M Strolin Benedetti; P Dostert
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.